DOI QR코드

DOI QR Code

Ultrasonographic assessment of transitional cell carcinoma of the urinary bladder in dogs: a perspective of tumor size change

  • Kim, Seungji (College of Veterinary Medicine and the Research Institute for Veterinary Science, Seoul National University) ;
  • Kim, Yongbaek (College of Veterinary Medicine and the Research Institute for Veterinary Science, Seoul National University) ;
  • Kim, Wanhee (College of Veterinary Medicine and the Research Institute for Veterinary Science, Seoul National University) ;
  • Choi, Mincheol (College of Veterinary Medicine and the Research Institute for Veterinary Science, Seoul National University) ;
  • Yoon, Junghee (College of Veterinary Medicine and the Research Institute for Veterinary Science, Seoul National University)
  • Received : 2017.03.24
  • Accepted : 2017.07.04
  • Published : 2017.09.30

Abstract

Study purposes were to evaluate ultrasonographic characteristics of transitional cell carcinoma (TCC) and quantitate bladder tumor size in dogs. Heterogeneous mass, wall involvement, and broad-based attachment were significantly associated with TCC, but not prominently the trigone region. Mass size evaluation revealed a significant correlation between progressive disease (PD) in TCC patients with piroxicam therapy. Largest diameter of target lesion/body weight (cm/kg) ratio showed a high mean value in PD. A value > 0.3 was associated with PD with 83% sensitivity and 66% specificity. The results suggest that ultrasonography can provide evidence for diagnosing and predicting a prognosis for TCC.

References

  1. Boria PA, Glickman NW, Schmidt BR, Widmer WR, Mutsaers AJ, Adams LG, Snyder PW, DiBernardi L, de Gortari AE, Bonney PL, Knapp DW. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005, 3, 73-80. https://doi.org/10.1111/j.1476-5810.2005.00070.x
  2. Fulkerson CM, Knapp DW. Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Vet J 2015, 205, 217-225. https://doi.org/10.1016/j.tvjl.2015.01.017
  3. Greene SN, Lucroy MD, Greenberg CB, Bonney PL, Knapp DW. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2007, 231, 1056-1060. https://doi.org/10.2460/javma.231.7.1056
  4. Hanazono K, Fukumoto S, Endo Y, Ueno H, Kadosawa T, Uchide T. Ultrasonographic findings related to prognosis in canine transitional cell carcinoma. Vet Radiol Ultrasound 2014, 55, 79-84. https://doi.org/10.1111/vru.12085
  5. Hume C, Seiler G, Porat-Mosenco Y, Caceres A, Shofer F, Sorenmo K. Cystosonographic measurements of canine bladder tumours. Vet Comp Oncol 2010, 8, 122-126. https://doi.org/10.1111/j.1476-5829.2010.00212.x
  6. Knapp DW, Glickman NW, DeNicola DB, Bonney PL, Lin TL, Glickman LT. Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urol Oncol 2000, 5, 47-59. https://doi.org/10.1016/S1078-1439(99)00006-X
  7. Knapp DW, Glickman NW, Widmer WR, DeNicola DB, Adams LG, Kuczek T, Bonney PL, DeGortari AE, Han C, Glickman LT. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000, 46, 221-226. https://doi.org/10.1007/s002800000147
  8. Knapp DW, McMillan SK. Tumors of the urinary system. In: Withrow SJ, Vail DM, Page RL (eds.). Withrow and MacEwen's Small Animal Clinical Oncology. 5th ed. pp. 572-582, Elsevier Saunders, Saint Louis, 2013.
  9. Knapp DW, Richardson RC, Chan TCK, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, Bonney P, Kuczek T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994, 8, 273-278. https://doi.org/10.1111/j.1939-1676.1994.tb03232.x
  10. Leveille R, Biller DS, Partington BP, Miyabayashi T. Sonographic investigation of transitional cell carcinoma or the urinary bladder in small animals. Vet Radiol Ultrasound 1992, 33, 103-107. https://doi.org/10.1111/j.1740-8261.1992.tb01969.x
  11. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002, 62, 356-358.
  12. Naughton JF, Widmer WR, Constable PD, Knapp DW. Accuracy of three-dimensional and two-dimensional ultrasonography for measurement of tumor volume in dogs with transitional cell carcinoma of the urinary bladder. Am J Vet Res 2012, 73, 1919-1924. https://doi.org/10.2460/ajvr.73.12.1919
  13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92, 205-216. https://doi.org/10.1093/jnci/92.3.205
  14. Valli VE, Norris A, Jacobs RM, Laing E, Withrow S, Macy D, Tomlinson J, McCaw D, Ogilvie GK, Pidgeon G, Henderson RA. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Pathol 1995, 113, 113-130. https://doi.org/10.1016/S0021-9975(05)80027-1